JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 299
- Registration Number
- NCT06287073
- Locations
- 🇰🇷
The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Soonchunhyang University Hospital Seoul, Seoul, Korea, Republic of
🇰🇷Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 84
- Registration Number
- NCT06280235
- Locations
- 🇨🇳
Hebei Mental Health Center, Baoding, China
🇯🇵Kaku Mental Clinic, Fukuoka-shi, Japan
🇺🇸Excell Research Inc., Oceanside, California, United States
A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems
- Conditions
- HealthyLiver Diseases
- Interventions
- Drug: Avenciguat (BI 685509)
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4
- Registration Number
- NCT06272058
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States
A Study in Healthy Men to Test How Different Doses of BI 3031185 Are Tolerated and How Food Influences the Amount of BI 3031185 in the Blood
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT06255340
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT06241560
- Locations
- 🇬🇪
LTD The First Medical Center, Tbilisi, Georgia
🇬🇪LTD "Aversi clinic", Tbilisi, Georgia
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 39
- Registration Number
- NCT06241573
- Locations
- 🇧🇬
ASMC-IPSMC-skin and Veneral Diseases, Sofia, Bulgaria
🇺🇸Clinical Trials Research Institute, Thousand Oaks, California, United States
🇦🇷STAT Research, Caba, Argentina
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- Conditions
- Idiopathic Pulmonary FibrosisProgressive Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1700
- Registration Number
- NCT06238622
- Locations
- 🇫🇷
HOP Avicenne, Bobigny, France
🇫🇷HOP de la Cavale Blanche, Brest, France
🇫🇷HOP Louis Pradel, Bron, France
A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 38
- Registration Number
- NCT06232252
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
- Conditions
- ObesityOverweight
- Interventions
- Drug: Placebo matching BI 456906
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 307
- Registration Number
- NCT06214741
- Locations
- 🇨🇳
Beijing Chao-Yang Hospital, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, China
🇨🇳Beijing Pinggu Hospital, Beijing, China
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity
- Conditions
- OverweightObesity
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 110
- Registration Number
- NCT06200467
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany